Our Website Uses Cookies 

We and the third parties that provide content, functionality, or business services on our website may use cookies to collect information about your browsing activities in order to provide you with more relevant content and promotional materials, on and off the website, and help us understand your interests and improve the website.

For more information, please contact us or consult our Privacy Notice.

Your binder contains too many pages, the maximum is 40.

We are unable to add this page to your binder, please try again later.

This page has been added to your binder.

Covington Advises Colbeck Capital Management on Kadmon Pharmaceuticals Acquisition

October 25, 2010

NEW YORK, October 25, 2010 — Kadmon Pharmaceuticals announced today that it has acquired Three Rivers Pharmaceuticals, a privately held specialty pharmaceuticals company based in Warrendale, Pennsylvania. Three Rivers will serve as the commercial and operational cornerstone for Kadmon, a privately held biopharmaceutical company based in New York City. Terms of the agreement were not disclosed. Covington & Burling LLP advised Colbeck Capital Management, LLC in the deal, the arranger of the debt financing for Kadmon.

The New York and Washington-based Covington team was led by partner Peter Schwartz and associate Chris Beals (corporate). Also advising on the transaction were partner John Hurvitz (life sciences), partner Jeffrey Elikan and associates Melody Wu and Michelle Morin (intellectual property), partner Michael Labson and associate Noellyn Davies (food & drug), and partner Rob Heller (tax).

Share this article: